NCT05746208 2026-03-17
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
University of California, San Francisco
Phase 2 Recruiting
Clinical Trials
9 trialsNCT02402920 2026-03-10
Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT04848337 2026-02-12
PLANE-PC
University of Michigan Rogel Cancer Center
Phase 2 Active not recruiting
NCT06232564 2026-01-14
PELICAN
Imperial College London
Phase 2 Active not recruiting
NCT03290079 2025-12-22
Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT03457948 2025-09-03
Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases
University of California, San Francisco
Phase 2 Active not recruiting
NCT03043664 2023-06-29
PLANET
Duke University
Phase 1/2 Completed
NCT03190213 2021-06-22
Pembro NEC
University of Utah
Phase 2 Terminated
NCT02939651 2021-03-09
A Study of Pembrolizumab in Patients With Neuroendocrine Tumors
Fox Chase Cancer Center
Phase 2 Completed